xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
Company profile
Ticker
XBIT
Exchange
Website
CEO
John Simard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
XBiotech USA, Inc. • XBiotech Germany GmbH ...
XBIT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Mar 24
8-K
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
4 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
SC TO-I/A
Issuer tender offer statement (amended)
20 Jun 23
SC TO-I
Issuer tender offer statement
17 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 202.19 mm | 202.19 mm | 202.19 mm | 202.19 mm | 202.19 mm | 202.19 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.84 mm | 3.09 mm | 495.67 k | 1.54 mm |
Cash used (since last report) | n/a | n/a | 18.94 mm | 20.62 mm | 3.31 mm | 10.26 mm |
Cash remaining | n/a | n/a | 183.25 mm | 181.58 mm | 198.88 mm | 191.93 mm |
Runway (months of cash) | n/a | n/a | 64.5 | 58.8 | 401.2 | 124.8 |
Institutional ownership, Q2 2023
14.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 8 |
Closed positions | 5 |
Increased positions | 11 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 20.33 bn |
Total shares | 4.33 mm |
Total puts | 5.20 k |
Total calls | 1.90 k |
Total put/call ratio | 2.7 |
Largest owners | Shares | Value |
---|---|---|
Millennium Management | 959.76 k | $5.70 bn |
Vanguard | 872.44 k | $5.18 bn |
Bay Street Financial | 844.86 k | $13.88 mm |
BLK Blackrock | 289.85 k | $1.72 bn |
Credit Suisse | 245.27 k | $1.46 bn |
Geode Capital Management | 173.18 k | $1.03 bn |
Bridgeway Capital Management | 126.68 k | $752.46 mm |
MS Morgan Stanley | 83.90 k | $498.34 mm |
Dimensional Fund Advisors | 74.31 k | $441.54 mm |
Connor, Clark & Lunn Investment Management | 64.29 k | $381.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 24 | John Simard | Convertible Loan Agreement Common Shares or Preferred Shares | Buy | Acquire P | No | No | 4.048001198208355 | 2,470,355 | 10.00 mm | 3,840,736 |
23 Jun 23 | W Thorpe Mckenzie | Director Stock Option Common Stock | Grant | Acquire A | No | No | 6.04 | 25,000 | 151.00 k | 25,000 |
23 Jun 23 | Donald H. MacAdam | Director Stock Option Common Stock | Grant | Acquire A | No | No | 6.04 | 25,000 | 151.00 k | 25,000 |
23 Jun 23 | Peter Libby | Director Stock Option Common Stock | Grant | Acquire A | No | No | 6.04 | 25,000 | 151.00 k | 25,000 |
23 Jun 23 | Waldin Jan-Paul | Director Stock Option Common Stock | Grant | Acquire A | No | No | 6.04 | 25,000 | 151.00 k | 25,000 |